Hospital Clínic de Barcelona - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 39

Hospital Clínic de Barcelona – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Hospital Clinic de Barcelona - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Hospital Clinic de Barcelona - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hospital Clinic de Barcelona human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hospital Clinic de Barcelona with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hospital Clinic de Barcelona’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Hospital Clinic de Barcelona - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hospital Clinic de Barcelona human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hospital Clinic de Barcelona with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hospital Clinic de Barcelona’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Hospital Clínic de Barcelona Snapshot
Key Facts
Hospital Clínic de Barcelona – Research and Development Overview
Key Therapeutic Areas
Hospital Clínic de Barcelona – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Hospital Clínic de Barcelona – Pipeline Products Glance
Hospital Clínic de Barcelona – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Hospital Clínic de Barcelona Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Hospital Clínic de Barcelona – Drug Profiles
aripiprazole
Product Description
Mechanism of Action
R&D Progress
Aripiprazole
Product Description
Mechanism of Action
R&D Progress
Enalapril + carvedilol
Product Description
Mechanism of Action
R&D Progress
Terlipressin + alpha adrenergic drugs (Dopamine and/or norepinephrine)
Product Description
Mechanism of Action
R&D Progress
testosterone
Product Description
Mechanism of Action
R&D Progress
Autologous Mesenchymal Stem Cells
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Vaccine
Product Description
Mechanism of Action
R&D Progress
Midodrine + Albumin
Product Description
Mechanism of Action
R&D Progress
Sirolimus
Product Description
Mechanism of Action
R&D Progress
Sodium Tungstate
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide
Product Description
Mechanism of Action
R&D Progress
MVA-B
Product Description
Mechanism of Action
R&D Progress
Hospital Clínic de Barcelona – Pipeline Analysis
Hospital Clínic de Barcelona – Pipeline Products by Therapeutic Class
Hospital Clínic de Barcelona Pipeline Products By Target
Hospital Clínic de Barcelona – Pipeline Products by Route of Administration
Hospital Clínic de Barcelona – Pipeline Products by Molecule Type
Hospital Clínic de Barcelona - Dormant Projects
Hospital Clínic de Barcelona – Locations And Subsidiaries
Head Office
Recent Developments
Aug 28, 2009: The Anti-Diabetic Effects Of Sodium Tungstate Revealed
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Charter Schools - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Education Services - Global Strategic Business Report
• Recreation as a Developmental Experience 130
• Recreation as a Developmental Experience: Theory Practice Research. New Directions for Youth Development. Number 130. J-B MHS Single Issue Mental Health Services
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans